Board summary
Key figures
72,952
Registered population
62.3% aged 18–64
17.0%
Aged 65+
ICB 14.9% · England 17.9%
19.0%
In IMD quintile 1
ICB 40.7% · England 21.0%
~13,996
Core20 residents (est.)
Resident basis; registered basis ~14,216 · see page 3
10,446
Hypertension register
+5.97% in 3 yrs · England +5.60%
846
SMI register
25.3% of Stockport (LAD)'s
1,442
COPD register
Reviews +0.65% in 3 yrs
Forecast to 2030
12,286
Hypertension patients, 2030
+1,840 on today
69.2%
QRISK ≥20% on statins, 2030
+1.88pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension control lags despite high BP recording.
Treatment to target fell 3.7 pp (England +2.5 pp) to 68.0% (Stockport 73.6%), despite 88.1% recent BP recording, which may reflect unverified titration gaps.
Annual asthma reviews fell behind benchmarks.
Asthma review coverage fell 3.1 pp (England +2.8 pp) to 59.6% (England 65.7%), leaving about 2,100 patients unreviewed across the PCN.
Diabetes HbA1c and statin delivery exceed England.
Diabetes HbA1c control without frailty reaches 60.2% (England 57.4%), while primary prevention statin prescribing in diabetes stands at 77.2% (England 73.2%).
Population, age and ethnicity
A younger population than Stockport sits alongside 31 catchment care homes
Across 72,952 registered patients, the PCN has a younger age profile than the borough. Patients aged 65+ comprise 17.0% (12,403 patients), below Stockport (19.7%) and England (17.9%), but above NHS Greater Manchester ICB (14.9%). Children aged 0-17 represent 20.7% (15,077 patients), above Stockport (19.7%) and England (19.6%), but below the ICB (21.8%). Census data record 0.0% Gypsy or Irish Traveller and 0.1% Roma residents. Practice lists range from 8,495 at Heaton Mersey Med.pract. to 54,561 at Heaton Moor Medical Group. Projected list growth to 2030 is 2.2%, though projection methodology is unverified.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Stockport LA) | 2,072 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Stockport LA) | 919 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Stockport LA) | 23.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 19.0% overall but practice shares vary by 40.0 percentage points
Across the PCN, 19.0% of registered patients live in Core20 areas, above Stockport (16.1%) but below England (21.0%). Deprivation is unevenly distributed: Manor Medical Practice has the highest concentration at 40.01% (3,959 estimated patients), Heaton Moor Medical Group holds the largest volume at 10,257 estimated patients (18.8%), and Heaton Mersey Med.pract. records 0.0%. Practice shares diverge by 40.0 pp, and weighted practice share (19.5%) slightly exceeds the PCN rate. Differentiated outreach must balance high practice concentration against large absolute patient volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
846
SMI register
1.17% recorded prevalence
414
Learning disability register
0.57% recorded prevalence
31
Care homes, 1,085 beds
In the PCN catchment
9.5%
Provide unpaid care
Stockport (LAD), Census 2021
Severe mental illness prevalence is 1.2% (846 patients), exceeding Stockport (1.0%), the ICB (1.1%), and England (1.0%). The learning disability register records 414 patients (0.6%, matching all benchmarks). The PCN catchment contains 31 care homes with 1,085 beds, though bed capacity does not establish occupancy or registered resident counts. Higher severe mental illness prevalence than borough and national rates indicates demand for routine physical health monitoring.
Severe mental illness: physical health checks
Across 846 severe mental illness patients (1.2% prevalence), blood pressure recording is 79.3% (Stockport 85.0%; England 83.4%) and BMI recording is 79.7% (Stockport 84.0%; England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,446
Hypertension register
+5.97%
Register growth, 3 yrs
Stockport (LAD) +4.99% · England +5.60%
−2.84pp
BP control, under 80
≤140/90 · −1.24pp aged 80+
+1,840
More patients by 2030
Forecast 12,286 (16.21%)
Hypertension case-finding and control
Hypertension prevalence is 14.4% (10,446 patients), below Stockport (16.2%) and England (15.2%), though recent blood pressure recording is 88.1% (Stockport 91.2%; England 90.0%). However, blood pressure control to threshold fell 3.7 pp over 2023 to 2025 (England +2.5 pp) to 68.0% (Stockport 73.6%; England 70.3%). Among patients aged under 80, control is 66.4% (Stockport 70.8%; England 67.8%), dropping to 65.3% at Heaton Moor Medical Group. Crude prevalence gaps may reflect the PCN's younger age profile rather than missed detection. Slipping control despite high recording suggests that post-screening medication titration and clinical review require PCN-wide prioritisation.
Lipids and statins
Statin treatment for diabetes without CVD reached 77.2% (England 73.2%; Stockport 74.2%), and QRISK 20% and over coverage is 65.3% (England 63.6%; Stockport 64.8%). Strong lipid-lowering therapy in high-risk cohorts places the PCN above national benchmarks, so sustaining routine annual review should remain the clinical priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 147,769 | £1.70 | £1.94 | £1.86 | £251,207 |
| Cardiovascular (all), 2025 | 201,215 | £2.84 | £3.15 | £3.33 | £571,451 |
For lipid-modifying drugs in 2026, the PCN prescribed 147,769 items at £1.70 per item (Stockport £1.99; NHS Greater Manchester ICB £1.94; England £1.86), spending £23,643 less than at England's unit cost. Spending less per item than England allows review capacity to focus on clinical appropriateness rather than formulary cost-cutting.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.00%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.60%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.6% (5,142 patients; England 6.6%), and asthma prescribing for ages 5–19 reached 1,760 items per 1,000 (England 1,488). However, annual asthma reviews fell 3.1 pp over 2023 to 2025 (England +2.8 pp) to 59.6% (Stockport 63.4%; England 65.7%), leaving about 2,100 patients unreviewed. Conversely, COPD reviews reached 78.2% (Stockport 76.4%; England 76.4%) even as the COPD register fell 5.7% (England +2.6%). Second-hand smoke status was recorded for 81.5% of asthma patients aged 6–19 (England 78.8%).
Cancer register and children's immunisation
The cancer register rose +11.4% over 2023 to 2025 (England +9.0%) to 2,917 patients (4.0% prevalence; England 3.8%). In childhood immunisations, MMR dose 1 reached 98.0% at age 5, but MMR dose 2 was 93.4% (below the 95.0% target by 1.6 pp; 4.6 pp below dose 1). The 4-in-1 pre-school booster was 88.3% (below the 95.0% target by 6.7 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of staged cancers were diagnosed at stage 1 or 2 (England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028. Staging completeness was 70.8% (England 67.0%), leaving about 2,270 additional early-stage diagnoses required annually across the ICB to reach the ambition. ICB staging describes system pathways, not PCN performance. Locally, the PCN cancer register grew +11.4% over 2023 to 2025 (England +9.0%) to 2,917 patients (4.0% prevalence). Breast screening coverage (aged 53 to 70) rose +19.6% over 2023 to 2024 (England +8.4%) to 67.8% (Stockport 72.6%; England 69.9%), with Heaton Moor Medical Group at 65.6%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Stockport NHS Foundation Trust recorded 83.2% on 28-day faster diagnosis (standard 75.0%) and 97.4% on 31-day treatment (standard 96.0%). However, 62-day referral to treatment was 74.7%, below the 85.0% standard by 10.3 pp, against Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%), Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). For diagnostic tests, 14.1% waited 6+ weeks at Stockport NHS Foundation Trust (Tameside and Glossop Integrated Care NHS Foundation Trust 0.8%; Manchester University NHS Foundation Trust 9.0%; England 23.1%). Provider data reflects trust performance, not the PCN.
| Pathways within standard (%) | Stockport | Manchester | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 83.21 | 80.06 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 97.39 | 92.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 74.67 | 72.85 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Stockport | Manchester | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 1.41 | 11.68 | 0.00 | 21.40 |
| CT | 2.93 | 14.66 | 0.18 | 9.92 |
| Echocardiography | 17.46 | 4.91 | 0.00 | 28.48 |
| Colonoscopy | 5.53 | 4.51 | 1.51 | 30.83 |
| Gastroscopy | 5.31 | 29.35 | 5.45 | 29.02 |
| All 15 DM01 tests | 14.08 | 8.98 | 0.80 | 23.14 |
| Community services activity | Stockport residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 57,085 | 573,310 |
| Referrals | 10,690 | 94,470 |
| Patients with a contact | 16,950 | 183,535 |
Community services (residents of Stockport), Jun 2026 (provisional). In June 2026, Stockport residents recorded 57,085 community care contacts, 7,980 care activities, and 16,950 individual patients with a contact, with adults aged 65+ accounting for 60.6% of contacts. Across NHS Greater Manchester Integrated Care Board, there were 573,310 contacts and 474,760 activities. Figures reflect provisional experimental data from submitting providers and do not establish unique PCN patient activity.
Practice variation and patient experience
GPPS phone access spans a 32.5 pp spread between network practices
Overall 2025/26 QOF achievement ranges from 96.5% at Heaton Mersey Med.pract. to 98.7% at Manor Medical Practice (England 92.5%). However, vaccination and immunisation domain achievement varies across a 17.3 pp spread, from 71.4% at Heaton Moor Medical Group to 88.7% at Manor Medical Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Manor Medical | 120 | 40.0 | 88.7% | 83.9% | 97.2% |
| Heaton Mersey | 93 | 0.0 | 84.3% | 68.4% | 85.1% |
| Heaton Moor | 131 | 18.8 | 56.2% | 65.1% | 75.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 tracked measures trail England's three-year change from 2023 to 2025
Across 25 tracked indicators, 15 measures trail England's three-year change. Trailing measures are led by heart failure reviews (-1.4% versus +8.7% in England over 2023 to 2025), asthma reviews (-5.0% versus +4.4%), and hypertension treatment to target (-5.2% versus +3.6%). Strengths include breast screening (+19.6% versus +8.4% in England, 2023 to 2024) and diabetes HbA1c control without frailty (+7.9% versus +4.4%, 2023 to 2025). Heart failure review coverage is 86.8% compared to 78.5% in England.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Hypertension treated to target
COPD register
BP control, under 80
Breast screening (53-70)
Diabetes HbA1c control
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Stockport (LAD) | Asset | PCN | Stockport (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 31 (1,085 beds) | n/a | Schools (catchment) | 119 | n/a |
| Children's centres | 2 | 2 | Places of worship | 68 | 135 |
| Libraries | 6 | 12 | Food banks (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 31 | 61 | Primary academies | 13 | 23 |
| Special schools | n/a | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension review for patients under 80
Across 10,446 hypertension patients, control under age 80 fell 2.8 pp over 2023 to 2025 (England +2.1 pp) to 66.4% (Stockport 70.8%; England 67.8%; 65.3% at Heaton Moor Medical Group). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review recall
Across 5,142 asthma patients (7.6% QOF prevalence vs England 6.6 percent), 12-month review coverage (denominator incl. PCAs) is 59.6% (Stockport (LAD) 63.4 percent; England 65.7 percent), after a 3-year change of -3.1 pp over 2023 to 2025 (England +2.8 pp), leaving 2,077 (about 2,100) patients without a recorded review. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Combined SMI physical health check outreach
Across 846 SMI patients (1.2% prevalence; England 1.0%), 12-month BP recording is 79.3% (Stockport 85.0%; England 83.4%) and BMI recording is 79.7% (Stockport 84.0%; England 82.1%). For discussion: practices could offer combined single-visit physical health checks, audit partial component coding, and raise shared-care data reconciliation with mental health system partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult resource allocation (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension clinical review protocol (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch-up (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Telephony and triage process review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension review for patients under 80 (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Combined SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
